立方制药(003020) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥811,816,818, representing a 29.14% increase compared to ¥628,617,238 in the same period last year[3] - Net profit attributable to shareholders was ¥66,141,680, marking a 40.35% increase from ¥47,126,894 in Q1 2022[3] - The company reported a basic earnings per share of ¥0.54, up 42.11% from ¥0.38 in the same quarter last year[3] - Operating profit for Q1 2023 was ¥77,924,247.11, up from ¥54,916,990.14 in Q1 2022, reflecting a growth of 41.9%[23] - Net profit attributable to the parent company for Q1 2023 was ¥66,141,680.02, compared to ¥47,126,894.93 in Q1 2022, representing a year-on-year increase of 40.4%[23] - Total operating revenue for Q1 2023 reached ¥811,816,818, an increase of 29.1% compared to ¥628,617,238.94 in the same period last year[22] Cash Flow and Investments - The net cash flow from operating activities increased by 54.12% to ¥21,600,909 from ¥14,015,957 in the previous year[3] - The total cash inflow from operating activities for Q1 2023 was ¥634,636,626.42, an increase of 22.3% compared to ¥518,954,386.03 in Q1 2022[24] - Cash outflow from investment activities totaled ¥401,060,831.39, a decrease of 18.4% from ¥491,727,786.23 in Q1 2022[25] - The net cash flow from investment activities was -¥401,062,190.31, compared to -¥491,734,373.18 in the previous year, indicating a reduction in cash outflow[25] - Cash inflow from financing activities was ¥42,452,002.44, with a net cash flow of ¥39,276,135.89, compared to a net outflow of -¥3,094,585.68 in Q1 2022[25] - The ending cash and cash equivalents balance was ¥237,039,230.28, significantly higher than ¥124,832,105.75 at the end of Q1 2022, marking an increase of 89.9%[25] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,306,025,264.82, an increase of 8.68% from ¥2,121,755,885.67 at the end of the previous year[3] - Total liabilities at the end of Q1 2023 were ¥753,233,707.58, an increase from ¥641,534,824.26 at the beginning of the year, reflecting a rise of 17.4%[19] - Current assets totaled ¥1,557,043,251.17 at the end of Q1 2023, compared to ¥1,452,547,083.20 at the beginning of the year, marking an increase of 7.2%[18] - Long-term equity investments increased significantly to ¥43,735,288.33 from ¥14,397,960.96, showing a growth of 203.5%[18] - The total equity attributable to the parent company increased to ¥1,552,791,557.24 from ¥1,480,221,061.41, representing a growth of 4.9%[20] Operational Highlights - The company experienced a 45.13% increase in accounts receivable, rising to ¥46,576,730 due to increased sales and credit terms[7] - The company’s operating costs rose by 34.70% to ¥51,519,690, corresponding to the revenue growth in the pharmaceutical sector[8] - The company received government subsidies amounting to ¥843,372.06 during the quarter, which is a decrease compared to previous periods[4] - The company received acceptance for the consistency evaluation of Metformin and Glimepiride tablets, and the registration application for Paliperidone raw materials[13] - The company approved the launch of Venlafaxine sustained-release tablets and Oxycodone sustained-release tablets during the reporting period[13] - The company participated in the national centralized procurement bidding for Nifedipine sustained-release tablets but did not win due to pricing factors[13] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,061[10] - The company’s top ten shareholders include various investment funds and individuals, with the largest shareholder holding 4,131,220 shares[12] Corporate Actions - The company is planning a major asset restructuring involving its wholly-owned subsidiary, Anhui Lifan Pharmaceutical Co., Ltd., to introduce new investors[14] - The company’s board approved the asset sale proposal related to Anhui Lifan Pharmaceutical on March 17, 2023[15] - The company held its first extraordinary general meeting of 2023 on March 31, 2023, to approve the asset sale and capital increase proposals[16] Miscellaneous - The report for Q1 2023 was not audited, indicating that the figures may be subject to change upon final review[26]